Recombinant protein was used as the immunogen for this AKR1B1 antibody.
AKR1B1, also deisgnated as aldose reductase, is a member of the aldo/keto reductase superfamily, which consists of more than 40 known enzymes and proteins. This protein catalyzes the reduction of a number of aldehydes, including the aldehyde form of glucose, and is thereby implicated in the development of diabetic complications by catalyzing the reduction of glucose to sorbitol. It has also been shown to have decreased expression in adrenocortical cancer, and possibly play a role in adrenal tumorigenesis. It has been suggested that AKR1B1 could be investigated as a marker of malignancy for adrenal tumor diagnosis.
0.2 mg/ml in 1X PBS with 0.1 mg/ml BSA (US sourced) and 0.05% sodium azide
Antibody Type:
Primary Antibody
Application Dilute:
Western blot: 0.5-1ug/ml,Immunofluorescence: 1-2ug/ml,Immunohistochemistry (FFPE): 0.5-1ug/ml for 30 min at RT
Application Notes:
The optimal dilution of the AKR1B1 antibody for each application should be determined by the researcher. 1. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.
* VAT and and shipping costs not included. Errors and price changes excepted
